Abstract
Broad-spectrum reactivator is an oxime which is able to reactivate acetylcholinesterase (AChE) inhibited by many kinds of organophosphate inhibitors of AChE, mainly nerve agents. There are many AChE reactivators (oximes) as suitable candidates for the broad-spectrum reactivator. Among them, oxime HI-6 is considered as number one, and due to its properties, it is recommended by many armies to be introduced as universal antidotal mean. In this study, we wanted to summarize that the designation “broad spectrum” is prerogative. For this purpose, in vivo evaluation of therapeutical dose of HI-6 (39.0 mg/kg) was performed. Soman, cyclosarin and tabun were used as the typical members of nerve agent family. According to the obtained results, oxime HI-6 did not sufficiently reactivate tabun-inhibited AChE. Brain AChE was also only partially protected. Based on these results, it seems that HI-6 in therapeutical dose has effect only in peripheral compartment.
Keywords: HI-6, Tabun, Cyclosarin, Soman, Broad-spectrum, Oxime
Letters in Drug Design & Discovery
Title: Potency of HI-6 to Reactivate Cyclosarin, Soman and Tabun Inhibited Acetylcholinesterase – In Vivo Study
Volume: 7 Issue: 7
Author(s): Jana Zdarova Karasova, Jiri Kassa, Miroslav Pohanka, Kamil Musilek and Kamil Kuca
Affiliation:
Keywords: HI-6, Tabun, Cyclosarin, Soman, Broad-spectrum, Oxime
Abstract: Broad-spectrum reactivator is an oxime which is able to reactivate acetylcholinesterase (AChE) inhibited by many kinds of organophosphate inhibitors of AChE, mainly nerve agents. There are many AChE reactivators (oximes) as suitable candidates for the broad-spectrum reactivator. Among them, oxime HI-6 is considered as number one, and due to its properties, it is recommended by many armies to be introduced as universal antidotal mean. In this study, we wanted to summarize that the designation “broad spectrum” is prerogative. For this purpose, in vivo evaluation of therapeutical dose of HI-6 (39.0 mg/kg) was performed. Soman, cyclosarin and tabun were used as the typical members of nerve agent family. According to the obtained results, oxime HI-6 did not sufficiently reactivate tabun-inhibited AChE. Brain AChE was also only partially protected. Based on these results, it seems that HI-6 in therapeutical dose has effect only in peripheral compartment.
Export Options
About this article
Cite this article as:
Zdarova Karasova Jana, Kassa Jiri, Pohanka Miroslav, Musilek Kamil and Kuca Kamil, Potency of HI-6 to Reactivate Cyclosarin, Soman and Tabun Inhibited Acetylcholinesterase – In Vivo Study, Letters in Drug Design & Discovery 2010; 7 (7) . https://dx.doi.org/10.2174/157018010791526269
DOI https://dx.doi.org/10.2174/157018010791526269 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prevalence of Comorbid Anxiety Disorders in Schizophrenia Spectrum Disorders: A Literature Review
Current Psychiatry Reviews Role of Oxygen Radicals on Bronchial Asthma
Current Drug Targets - Inflammation & Allergy Chondroitin Sulfate and Sulfur Containing Chondroprotective Agents: Is there a Basis for their Pharmacological Action?
Current Rheumatology Reviews Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
Current Pharmaceutical Design Cytokines and Invertebrates: TGF-β and PDGF
Current Pharmaceutical Design Microwave Assisted Organic Synthesis (MAOS) of New Dispacamide A Derivatives Bearing a Thiazolinone Platform, Biological Assays on Inhibition of Protein Kinases and Cell Effects
Current Microwave Chemistry FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals Fruitless Wolfberry-Sprout Extract Rescued Cognitive Deficits and Attenuated Neuropathology in Alzheimer’s Disease Transgenic Mice
Current Alzheimer Research Editorial (Thematic Issue: The Activity of Products From Cnidaria: A Therapeutic Tool in Neurological Diseases? Part II)
Central Nervous System Agents in Medicinal Chemistry Small Molecule Antagonists of Integrin Receptors
Current Medicinal Chemistry Author Index To Volume 3
Current Alzheimer Research Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia
Current Topics in Medicinal Chemistry Vitamin-D in the Immune System: Genomic and Non-Genomic Actions
Mini-Reviews in Medicinal Chemistry The Effect of Tumour Necrosis Factor-α on Periodontal Ligament Stem Cell Differentiation and the Related Signaling Pathways
Current Stem Cell Research & Therapy Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
Current Cancer Drug Targets ACKNOWLEDGEMENTS TO REVIEWERS
CNS & Neurological Disorders - Drug Targets Induction of Cellular Oxidative Stress by the β-amyloid Peptide Involved in Alzheimers disease
Protein & Peptide Letters Meet Our Editorial Board Member
Current Gene Therapy